$-0.33
(Market cap
$92 Mln
Recently Viewed
Clear AllMarket cap
$92 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
7.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-4.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.3
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
28,599,300
CFO
$-188.48 Mln
EBITDA
$-182.40 Mln
Net Profit
$-277.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
| 18.9 | 3.7 | 0.0 | -14.0 | -46.5 | -36.9 | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
| -4.8 | -61.0 | -85.2 | -9.2 | 6.2 | 63.0 | -70.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
2.8 | 91.5 | 3.8 | -58.2 | -1,349.4 | -584.1 | -- | 7.9 |
| 129.5 | 8,371.7 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.4 | |
| 0.9 | 53.7 | 9.2 | -64.5 | -550.5 | -67.5 | -- | 0.7 |
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing... DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Read more
President, CEO & Director
Mr. Joshua Riggs
President, CEO & Director
Mr. Joshua Riggs
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of OncoCyte Corp (OCX) is $2.83 (NASDAQ) as of 17-Jul-2025 09:30 EDT. OncoCyte Corp (OCX) has given a return of -46.46% in the last 3 years.
Since, TTM earnings of OncoCyte Corp (OCX) is negative, P/E ratio is not available.
The P/B ratio of OncoCyte Corp (OCX) is 7.92 times as on 17-Jul-2025, a 80 premium to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of OncoCyte Corp (OCX) are Rs 4.75 and Rs 1.92 as of 27-Apr-2026.
OncoCyte Corp (OCX) has a market capitalisation of $ 92 Mln as on 17-Jul-2025. As per SEBI classification, it is a Small Cap company.
Before investing in OncoCyte Corp (OCX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.